This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Epigenomics Gestione

Gestione criteri di controllo 1/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Noel Doheny

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	13.2yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Noel Doheny

13.2yrs

Mandato

Dr. Noel Thomas Doheny has been the Chief Executive Officer of Epigenomics Inc. at Epigenomics AG since May 2011. Dr. Doheny manages all US activities and global business development and partnership develo...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Helge Lubenow	Chairman of the Supervisory Board	8.2yrs	€25.00k	Nessun dato
Alexander Link	Vice-chairman of Supervisory Board	4.1yrs	€25.00k	Nessun dato
Jochen Hummel	Member of Supervisory Board	less than a year	Nessun dato	Nessun dato

4.1yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: ECX's board of directors are considered experienced (4.1 years average tenure).

This company listing is no longer active

Epigenomics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Epigenomics AG, Annual General Meeting, May 29, 2024

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Price target increased by 227% to €52.65

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 11%

Epigenomics AG, Annual General Meeting, May 29, 2024

New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.

Consensus revenue estimates increase by 139%

Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)

Now 30% undervalued

New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.

Now 23% undervalued

A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m

Price target increased by 9.1% to €6.00

First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)

Price target increased to €1.17

Consensus forecasts updated

No longer forecast to breakeven

Third quarter 2022 earnings released

Epigenomics AG to Report Q3, 2023 Results on Nov 09, 2023

Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released

Price target decreased to €0.98

Epigenomics AG Confirms Outlook for Fiscal Year 2022

Price target increased to €1.07

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epigenomics AG Confirms Earnings Guidance for the Year 2022

Price target decreased to €0.95

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €0.95

Third quarter 2021 earnings released: EPS €0.23 (vs €0.47 loss in 3Q 2020)

Price target decreased to €1.14

New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.

Second quarter 2021 earnings released: €0.21 loss per share (vs €0.57 loss in 2Q 2020)

Price target decreased to €1.44

We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

Consensus forecasts updated

Forecast to breakeven in 2023

First quarter 2021 earnings released: €0.20 loss per share (vs €0.55 loss in 1Q 2020)

Epigenomics AG Announces Earnings Guidance for the Year 2021

Consensus forecasts updated

Consensus forecasts updated

Epigenomics AG Provides Earnings Guidance for the Year 2021

New 90-day low: €2.30

When Will Epigenomics AG (ETR:ECX) Breakeven?

Price target lowered to €16.27

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer Screening

Epigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021

Epigenomics AG Pulls Revenue Guidance for the Year 2020 Due to Covid-19

Epigenomics AG announces the U.S. Centers for Medicare & Medicaid Services have issued a negative reimbursement proposal in connection with the National Coverage Determination of Epi proColon, Epigenomics' blood test for colorectal cancer screening

Epigenomics Ag Pulls Its Revenue Guidance for 2020

Earnings released

New 90-day high - €2.17

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media